MTOR and neoplasm: In this regard, inhibiting CD109 is known to reduce EGFR signaling, suppress the Akt/mTOR pathway, and increase tumor cell sensitivity to EGFR inhibitors, highlighting its potential as a promising therapeutic target in lung cancer (83).